Heron Therapeutics (HRTX) Stock
Small cap biopharma for oncology supportive care and pain. Here's the price, business snapshot, and what's worth knowing about Heron Therapeutics in September 2026.
Heron Therapeutics, Inc. (HRTX) is a small‑cap biopharmaceutical company focused on developing and commercialising treatments for supportive care in oncology and acute pain management. The company has pursued a mix of marketed products and partnered programmes aimed at reducing chemotherapy‑related side effects and improving postsurgical pain control. With a market capitalisation of approximately $238.3 million, Heron operates in a high‑volatility, data‑driven sector where clinical results, regulatory actions and commercial uptake can materially affect valuation. Revenue streams for firms of this size are often lumpy and may rely on licensing deals or collaborations; additional capital raises are not uncommon. This summary is educational and not personalised investment advice — potential investors should review the latest financial statements, regulatory filings and investor presentations, and consider their risk tolerance and diversification needs before acting.
Heron Therapeutics (HRTX) Stock Forecast
Analyst price target, next 12 months
$6.67
+2166.0% vs today's $0.29
Price range over the last 12 months
Close to its 12-month low
Analysts covering Heron Therapeutics have a consensus 12-month target of $6.67, above the current price of $0.29.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 25 May 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Heron Therapeutics' stock with a target price of $6.67, indicating potential growth.
Financial Health
Heron Therapeutics is generating solid revenue and cash flow, with a strong profit margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical Catalyst Watch
Upcoming clinical readouts and regulatory milestones can move the share price; positive data may lift sentiment, though trial outcomes are uncertain.
Commercial & Partnerships
Revenue often depends on product uptake and licensing deals; partnerships can broaden reach but terms and milestone risks vary.
Small‑cap Volatility
With a market cap near $238M, liquidity can be limited and price swings larger than for bigger peers; consider diversification and risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
